Collegium   
Collegium Pharmaceuticals is a developer of late stage specialty pharmaceutical products derived from approved or about to be approved chemical entities. The company was founded by the team that also founded Copley Pharmaceuticals, a highly successful generic pharmaceutical company. The company’s management is highly experienced in drug formulation techniques and drug delivery, and, as such, are positioned to exploit profitable niches in the pharmaceutical market. Collegium applies proprietary formulation techniques to produce products with improved therapeutic performance. This may involve, for example, combining two different drugs into a single formulation in which the delivery and absorption of the two components is controlled to produce a therapeutic effect. Collegium creates value through performing internal “proof of concept” and out-licensing to suitable marketing partners or in certain cases obtaining regulatory approval and marketing the products themselves. For approved chemical entities, the Company uses regulatory paths that do not require large clinical trials to gain approval. In this way, the cost, time and risk associated with clinical trials is avoided, even as valuable intellectual property rights are maintained. The company already has developed or in-licensed multiple proprietary formulation and drug delivery platforms that are applicable both to new drugs and drugs about to come off patent. Thus, the company’s products and services enable pharmaceutical and biotech companies to improve performance of their products and extend patent lives. At the same time, they enable generic pharmaceutical companies to enhance financial performance by marketing proprietary formulations.